
In-line Performance: Revenue grew by 13% y/y to Rs38.4bn vs. our estimate of Rs41.8bn. EBITDA fell 5% YoY to Rs3.86bn vs. our estimate of Rs4.87bn, mainly due to lower-than-expected revenue and higher other expenses. EBITDA margin contracted by 190bps YoY to 10.1% vs. our estimate of 11.6%. Other expenses grew 10% YoY and 2% QoQ to Rs5.31bn. Accordingly, APAT grew 4% YoY to Rs1.88bn vs. our estimate of Rs2.66bn, mainly due to lower operating profit. New energy revenue grew 37% YoY to Rs2.3bn. It incurred Rs416mn EBIT loss in Q2FY27 vs. Rs487mn EBIT loss in Q2FY26. Its board has approved an LFP prismatic cell gigafactory (~5GWh) plus pack assembly with ~Rs23.2bn capex and to be completed within 30 months. It will serve stationary applications first, then mobility.
Outlook and Valuation: We trim our EPS estimate by 8-13% for FY27/28e, due to higher input/interest cost and lower other income. We upgrade our rating on the stock to BUY with lower TP of Rs990 (from Rs1,080 earlier), valuing the parent entity at 11x Sep-28e EPS (vs. 12x Mar-28e previously), ARACT NPV at Rs222 (from Rs210 earlier) and BESS at Rs155 (vs. Rs146 earlier). Increase in TP for ARACT and BESS is attributable to rolling over our valuation to Sep-28. Expecting ARACT’s revenue/PAT at Rs43.2/2.16bn by FY31e, we assign 25x multiple on discounted PAT. Further, we expect BESS revenue/PAT at Rs44.8/1.34bn by FY30e, we assign 25x valuation multiple on discounted PAT.
Key Risks: (a) Weaker growth in lead batteries; (b) lower orders for lithium-ion cell/BESS plant; and (c) adverse commodity prices.
No comments:
Post a Comment